Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, cervical cancer and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal women with osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody. The company also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype that targets interleukin-4 receptor subunit a in phase 2 clinical trial; BA1106, a non-IL-2 blocking anti-CD25 antibody; BA1202, a novel bi-specific antibody drug that targets CEA/CD3; BA1301, an ADC candidate that targets Claudin 18.2; and BA1302, a novel CD228-directed ADC. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.